A Tolerability and Pharmacokinetic Study of Adjuvant Erlotinib and Capecitabine with Concurrent Radiation in Resected Pancreatic Cancer

BACKGROUND: Erlotinib is approved for the treatment of advanced pancreas cancer. We conducted a prospective trial to determine the safety profile and recommended phase 2 dose of erlotinib and capecitabine given concurrently with intensity-modulated radiation therapy (IMRT) in resected pancreatic can...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Ma, Wen Wee, Herman, Joseph M, Jimeno, Antonio, Laheru, Daniel, Messersmith, Wells A, Wolfgang, Christopher L, Cameron, John L, Pawlik, Timothy M, Donehower, Ross C, Rudek, Michelle A, Hidalgo, Manuel
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Neoplasia Press Inc. 2010
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3000462/
https://ncbi.nlm.nih.gov/pubmed/21151476
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia